Concord Biotech Limited (NSE:CONCORDBIO)
India · Delayed Price · Currency is INR 603.50
+6.30 (1.05%)
Nov 12, 2026, 3:30 PM IST
Concord Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 11,704 | 10,549 | 12,001 | 10,169 | 8,532 | 7,129 | |
Revenue Growth | 4.02% | -12.10% | 18.01% | 19.20% | 19.67% | 15.56% |
Cost of Revenue | 4,254 | 3,783 | 4,317 | 3,498 | 1,921 | 1,719 |
Gross Profit | 7,450 | 6,766 | 7,684 | 6,672 | 6,611 | 5,410 |
Selling, General & Admin | 1,905 | 1,769 | 1,389 | 1,230 | 1,103 | 956.96 |
Other Operating Expenses | 1,389 | 1,209 | 1,122 | 1,038 | 1,969 | 1,662 |
Operating Expenses | 4,041 | 3,723 | 3,055 | 2,804 | 3,612 | 3,120 |
Operating Income | 3,409 | 3,043 | 4,628 | 3,868 | 2,999 | 2,290 |
Interest Expense | -2.35 | -2.83 | -5.29 | -25.52 | -45.1 | -54.84 |
Interest & Investment Income | 24.63 | 24.63 | 17.1 | 30.41 | 44.41 | 47.87 |
Earnings From Equity Investments | -2.56 | 29.09 | -13.22 | 33.71 | 19.59 | -36.38 |
Currency Exchange Gain (Loss) | 160.2 | 160.2 | 81.98 | 64.81 | 102.22 | 63.59 |
Other Non Operating Income (Expenses) | -26.57 | 13.77 | 16.22 | 12.41 | 57.93 | 9.73 |
EBT Excluding Unusual Items | 3,562 | 3,268 | 4,725 | 3,983 | 3,178 | 2,320 |
Gain (Loss) on Sale of Investments | 211.28 | 211.28 | 222.64 | 140.65 | 37.17 | 52.3 |
Gain (Loss) on Sale of Assets | 0.13 | 0.13 | -2.25 | 0.12 | -0.94 | -0.34 |
Other Unusual Items | -32.75 | -32.75 | - | - | -0.31 | - |
Pretax Income | 3,741 | 3,446 | 4,946 | 4,126 | 3,220 | 2,375 |
Income Tax Expense | 946.78 | 854.18 | 1,229 | 1,045 | 819.28 | 625.89 |
Earnings From Continuing Operations | 2,794 | 2,592 | 3,716 | 3,081 | 2,401 | 1,749 |
Minority Interest in Earnings | 30.7 | 16.77 | - | - | - | - |
Net Income | 2,824 | 2,609 | 3,716 | 3,081 | 2,401 | 1,749 |
Net Income to Common | 2,824 | 2,609 | 3,716 | 3,081 | 2,401 | 1,749 |
Net Income Growth | -12.81% | -29.80% | 20.62% | 28.33% | 37.25% | -25.53% |
Shares Outstanding (Basic) | 210 | 209 | 209 | 209 | 209 | 209 |
Shares Outstanding (Diluted) | 210 | 209 | 209 | 209 | 209 | 209 |
Shares Change | 0.25% | - | - | - | - | - |
EPS (Basic) | 13.43 | 12.47 | 17.76 | 14.73 | 11.47 | 8.36 |
EPS (Diluted) | 13.43 | 12.47 | 17.76 | 14.73 | 11.47 | 8.36 |
EPS Growth | -13.03% | -29.80% | 20.62% | 28.33% | 37.25% | -25.52% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 1,824 | 1,717 | 1,333 | 1,798 | 1,009 | 526.36 |
Free Cash Flow Per Share | 8.67 | 8.21 | 6.37 | 8.59 | 4.82 | 2.52 |
Dividend Per Share | - | 3.775 | 5.350 | 4.375 | 3.415 | 2.560 |
Dividend Growth | - | -29.44% | 22.29% | 28.11% | 33.40% | -24.05% |
Gross Margin | 63.65% | 64.14% | 64.03% | 65.61% | 77.49% | 75.89% |
Operating Margin | 29.12% | 28.85% | 38.57% | 38.03% | 35.15% | 32.12% |
Profit Margin | 24.13% | 24.73% | 30.97% | 30.30% | 28.14% | 24.54% |
Free Cash Flow Margin | 15.58% | 16.28% | 11.11% | 17.68% | 11.83% | 7.38% |
EBITDA | 4,138 | 3,769 | 5,154 | 4,386 | 3,527 | 2,778 |
EBITDA Margin | 35.35% | 35.73% | 42.95% | 43.13% | 41.33% | 38.97% |
D&A For EBITDA | 728.97 | 725.89 | 526.08 | 518.51 | 527.85 | 487.98 |
EBIT | 3,409 | 3,043 | 4,628 | 3,868 | 2,999 | 2,290 |
EBIT Margin | 29.12% | 28.85% | 38.57% | 38.03% | 35.15% | 32.12% |
Effective Tax Rate | 25.31% | 24.78% | 24.85% | 25.32% | 25.44% | 26.35% |
Revenue as Reported | 12,187 | 11,072 | 12,445 | 10,507 | 8,885 | 7,364 |